Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abelacimab - Anthos Therapeutics

Next Previous
Search
Drug Profile

Abelacimab - Anthos Therapeutics

Alternative Names: anti-FXI mAb; FXI antibody; MAA-868

Latest Information Update: 16 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Developer Anthos Therapeutics; Labcorp Drug Development; Novartis Pharmaceuticals; TIMI Study Group
  • Class Antiarrhythmics; Anticoagulants; Antithrombotics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Factor XI inhibitors; Factor XIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atrial fibrillation; Venous thromboembolism
  • Phase II Stroke; Thrombosis

Most Recent Events

  • 03 Apr 2025 Anthos Therapeutics has been acquired by Novartis
  • 29 Mar 2025 Updated efficacy and safety data from a phase II AZALEA-TIMI 71 trial in Stroke released by Anthos Therapeutics
  • 22 Jan 2025 Updated efficacy data from a phase II AZALEA-TIMI 71 trial in Stroke (Prevention) released by Anthos Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top